65,437 trials
Diabetic Macular Edema (DME)
Primary: Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 8 — 9.43; 8.85 letters
Sedentary Lifestyle
Primary: Change in Time Spent Sitting or Lying Down at 6 Months — -40.36; -8.51 Minutes — p=0.003
Health Literacy
Primary: The Degree of Differential Item Functioning (DIF) in NIH Patient-Reported Outcomes Measurement Information System (PROMIS Profile 57 v 2.0) Anxiety Subscale — 0.06; 0.02…
Cutaneous Neurofibroma · Neurofibromatosis Type 1 · Optic Nerve Glioma
Primary: Median Best Response of Cutaneous Neurofibromas in Participants With at Least One Restaging Evaluation — -28.5 percent change
Colorectal Carcinoma
Primary: Number of Participants to Return Fecal Immunochemical Test (FIT) — 3; 4; 9 Participants
Coronavirus Disease 2019 (COVID-19) · SARS-CoV-2
Primary: Number of Index Participants and Their Household Contacts With SARS-CoV-2 RNA Detection in Nasal Samples Over the Study/Surveillance Period — 98.9; 99.2; 99.1; 98.0…
Recurrent Lymphoproliferative Disorder · Refractory Lymphoproliferative Disorder
Primary: Overall Response Rate — 0 percentage of participants
FSGS · Focal Segmental Glomerulosclerosis · Glomerulosclerosis
Primary: Change From Baseline in UPCR at Week 12 — 0.83; 1.02; 1.12; 0.87 g protein/g creatinine — p=0.1924
Gastric Procedures · Lung Resection Procedures
Primary: Number of Participants Who Experienced Specific Device-related Adverse Events (AEs) Through 70 Days Post Gastric Resection Procedures — 0; 1; 0 Participants
Healthy Volunteers Only
Primary: Utilization of Toy — .45; .49; .50; .53 Proportion
Coronary Artery Bypass Surgery · Postoperative Complications · Heart Failure
Primary: Postoperative Increase of Plasma NT-proBNP — 5390; 6452 ng/L — p=0.086
Asthma
Primary: Change in Number of Exacerbations of the Participants — 2.77; 1.32 Change in number of courses of oral c
Polycystic Ovary Syndrome (PCOS) · Overweight · Obesity
Primary: Assessment of Reproductive Functions — 5.52; 5.33 mIU/ml
Multiple Sclerosis · Cognitive Impairment
Primary: Processing Speed Change From Baseline Assessment — 41.65; 42.05; 44.4; 46.1 score on a scale
Constipation · Parkinson Disease
Primary: The Number of Participants Who Experience Treatment Related Adverse Events-Safety Endpoint — 44; 7 Participants